

Zai Lab Announces Upcoming Presentations at September Conferences

August 26, 2019

SHANGHAI, China and SAN FRANCISCO, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Zai Lab Limited ("Zai Lab" or "the Company") (NASDAQ: ZLAB), a China and US-based innovative commercial-stage biopharmaceutical company, today announced that members of the senior management team will be presenting at the following upcoming conferences this September. Details of the conferences are as follows:

Citi's 14th Annual Biotech Conference

Presentation: Thursday, September 5, 2019 at 10:15 a.m. EDT

Presenter: Dr. Samantha Du, Founder & Chief Executive Officer, Tao Fu, President & Chief Operating Officer, and Jonathan Wang, Head of Business

Development

Location: Boston, MA

J.P. Morgan China Healthcare CEO-CFO Forum, China BioMed Innovation and Investment Conference

Date: Friday, September 20, 2019 at 11:30 a.m. CST

Presenter: Billy Cho, Chief Financial Officer

Location: Suzhou, China

About Zai Lab

Zai Lab (NASDAQ: ZLAB) is a China and U.S.-based innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. Zai Lab's experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates targeting the fast-growing segments of China's pharmaceutical market and addressing unmet medical needs. Zai Lab's vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its partners' and its own products in order to impact human health worldwide.

Contact:

Zai Lab Billy Cho, CFO +86 137 6151 2501 billy.cho@zailaboratory.com

Media: Ryo Imai / Robert Flamm, Ph.D. Burns McClellan, on behalf of Zai Lab

212-213-0006, ext. 315 / 364, <u>rimai@burnsmc.com</u> / <u>rflamm@burnsmc.com</u>

Investors: Lee Roth

Burns McClellan, on behalf of Zai Lab 212-213-0006, ext. 331, lroth@burnsmc.com



Source: Zai Lab Limited